Related Experiment Video
Updated: Jul 10, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
43.8K
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
Jessica Huston1, Hannah Schaffner2, Alyssa Cox1
1College of Pharmacy, University of Florida, Jacksonville, USA.
Summary
Icosapent ethyl (IPE) is an FDA-approved fish oil derivative that lowers cardiovascular risk by reducing triglyceride levels. Clinical data review supports its cardiovascular benefits in patients with atherosclerotic cardiovascular disease (ASCVD).
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Icosapent ethyl (IPE) is the first fish oil product approved by the FDA for reducing atherosclerotic cardiovascular disease (ASCVD) risk.
- IPE, an esterified form of eicosapentaenoic acid (EPA), functions as a prodrug.
- Initially indicated for hypertriglyceridemia, IPE's role has expanded with further research.
Purpose of the Study:
- To critically review the clinical data on the cardiovascular benefits of IPE in ASCVD patients.
- To evaluate the therapeutic value of IPE for individuals with elevated triglyceride (TG) levels.
Main Methods:
- Review of clinical trial data and subanalyses concerning IPE.
- Assessment of studies investigating IPE's effects on cardiovascular outcomes.
- Analysis of subanalyses focusing on patient subgroups (sex, statin use, inflammatory markers).
Main Results:
- IPE demonstrates cardiovascular benefits in patients with ASCVD.
- TG reduction is a primary mechanism of IPE's action.
- Subanalyses explore effects across diverse patient populations and inflammatory profiles.
Conclusions:
- IPE is a valuable treatment option for patients with ASCVD and elevated TG.
- Further research continues to elucidate the multifaceted benefits of IPE.
- IPE's impact on cardiovascular risk reduction is supported by extensive clinical data.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...